FINWIRES · TerminalLIVE
FINWIRES

Trendlines公司研发的药物获得美国FDA批准开展膀胱治疗二期临床试验;股价飙升5%。

By

-- 据周一提交给新加坡交易所的文件显示,Trendlines(SGX:42T)旗下子公司Vensica Medical已获得美国食品药品监督管理局(FDA)批准,启动其VixE药物输送系统的二期临床试验。 这家医疗及其他服务公司的股价在周二的交易中上涨了近5%。 该无针输送系统正在研发用于治疗膀胱过度活动症,预计二期临床试验将在美国和欧洲招募约210名患者。

Related Articles

Asia

WinWay Technology Logs About NT$699 Million in Q1 Profit; Shares Gain 6%

WinWay Technology (TPE:6515) posted a profit attributable to owners of NT$698.6 million, or NT$19.54 per share, for the first quarter, according to a Monday filing with the Taiwan Stock Exchange.Shares rose 6% in Tuesday's midday trade.Meanwhile, operating revenue stood at NT$2.98 billion.

$TPE:6515
International

RBA Press Conference: The Oil Shock Is Not the Sole Reason Behind Rate Hikes, Australia Had an Inflation Problem Before This, Says Bullock

$^AXJO
US Markets

AB InBev's First-quarter Revenue Climbs on Beer, No-alcohol Portfolio Growth

Anheuser-Busch InBev (ABI.BR, ANH.JO), d/b/a AB InBev, on Tuesday reported solid first-quarter performance due to the rise in demand for its beer and no-alcohol product lines.For the three months ended March 31, the Belgian brewer saw its total revenue rise 5.8% on an organic basis to $15.27 billion, aided by a 4.5% increase in revenue per hectoliter. AB InBev said revenue management, as well as a positive mix from premiumization and the Beyond Beer portfolio, bolstered its top line.Volumes ticked up 0.8% from the previous year, with beer volumes gaining 1.2%, while non-beer fell 1.9%. The owner of brands like Stella Artois, Corona and Michelob Ultra noted that the company achieved an all-time high in first-quarter volumes across Mexico, Colombia, Brazil, South Africa, and Peru. AB InBev also estimated that it gained or held share in 75% of its markets on the back of the acceleration of its megabrands and Beyond Beer line.Profit attributable to equity holders for the quarter came in at $2.56 billion, up from $2.15 billion a year ago. Basic EPS moved to $1.30 from $1.08, while underlying EPS grew to $0.97 from $0.81 earlier.Against this backdrop, the brewer reiterated its full-year 2026 EBITDA growth target of 4% to 8%, aligning with its midterm outlook."We had been nervous that ABI's 1Q results wouldn't do justice to the strong share price in the lead up. In the event, the results were good, with organic sales growth 280 [basis points] ahead of consensus - a function of volume and price - with every region exceeding expectations," RBC Capital Markets said in a quick-take note following the earnings release.

$ABI.BR$ANH.JO